Cargando…
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII products. Bypassing agents to control bleeding episodes are recommended for these patients, but their efficacy is diff...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606027/ https://www.ncbi.nlm.nih.gov/pubmed/34849451 http://dx.doi.org/10.1002/rth2.12631 |